-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by Cantor Fitzgerald
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by Cantor Fitzgerald
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research note issued on Monday, PriceTargets.com reports.
A number of other research analysts have also issued reports on the company. Raymond James raised ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price on the stock in a report on Friday, August 12th. HC Wainwright dropped their price target on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $5.00.
Get ProQR Therapeutics alerts:ProQR Therapeutics Price Performance
Shares of NASDAQ PRQR opened at $0.87 on Monday. ProQR Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.09. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.14. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market cap of $62.02 million, a P/E ratio of -0.87 and a beta of 0.80.
Hedge Funds Weigh In On ProQR Therapeutics
Several large investors have recently made changes to their positions in the company. Monaco Asset Management SAM acquired a new position in ProQR Therapeutics in the first quarter valued at about $82,000. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 10.0% in the first quarter. Privium Fund Management B.V. now owns 5,244,446 shares of the biopharmaceutical company's stock worth $4,747,000 after acquiring an additional 478,787 shares in the last quarter. Prosight Management LP increased its holdings in shares of ProQR Therapeutics by 68.0% in the first quarter. Prosight Management LP now owns 599,288 shares of the biopharmaceutical company's stock worth $542,000 after acquiring an additional 242,671 shares in the last quarter. M28 Capital Management LP bought a new stake in shares of ProQR Therapeutics in the first quarter worth about $907,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock worth $31,346,000 after acquiring an additional 481,325 shares in the last quarter.ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research note issued on Monday, PriceTargets.com reports.
據PriceTargets.com報道,在週一發佈的一份研究報告中,康託·菲茨傑拉德的研究分析師將ProQR治療公司(納斯達克:PRQR-GET評級)的評級從“增持”下調至“中性”。
A number of other research analysts have also issued reports on the company. Raymond James raised ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price on the stock in a report on Friday, August 12th. HC Wainwright dropped their price target on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $5.00.
其他一些研究分析師也發佈了關於該公司的報告。雷蒙德·詹姆斯在8月12日(星期五)的一份報告中將ProQR治療公司的評級從“市場表現”上調至“跑贏大盤”,併為該股設定了2.00美元的目標價。在5月9日星期一的一份研究報告中,HC Wainwright將他們對ProQR治療的目標價從4.00美元下調至2.00美元。Chardan Capital在8月12日星期五的一份研究報告中將ProQR治療公司的評級從“買入”下調至“中性”。最後,StockNews.com在5月9日星期一的一份研究報告中將ProQR治療公司的評級從“賣出”上調至“持有”。五名研究分析師對該股的評級為持有,四名分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司的普遍評級為持有,平均目標價為5.00美元。
ProQR Therapeutics Price Performance
ProQR治療藥物性價比
Shares of NASDAQ PRQR opened at $0.87 on Monday. ProQR Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.09. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.14. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market cap of $62.02 million, a P/E ratio of -0.87 and a beta of 0.80.
週一,納斯達克PRQR的股價開盤報0.87美元。ProQR Treateutics的52周低點為0.53美元,52周高位為9.09美元。該公司的50日簡單移動均線切入位為0.80美元,200日簡單移動均線切入位為1.14美元。該公司的速動比率為5.93,流動比率為5.93,債務權益比率為0.43。該股市值為6,202萬美元,市盈率為-0.87,貝塔係數為0.80。
Hedge Funds Weigh In On ProQR Therapeutics
對衝基金對ProQR治療公司的看法
ProQR Therapeutics Company Profile
ProQR治療公司簡介
(Get Rating)
(獲取評級)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物製藥公司,致力於發現和開發基於RNA的治療遺傳疾病的療法。它主要開發正處於II/III期臨牀試驗的sepofarsen,用於治療Leber先天性黑髮10病的照明試驗;以及正在進行II/III期臨牀試驗的ultevursen,用於治療USH2A介導的視網膜色素變性和USHER綜合徵。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
- 免費獲取StockNews.com關於ProQR治療(PRQR)的研究報告
- 這3只電子遊戲股票現在還在玩嗎?
- 2輛長期電動汽車的交易價格低於20美元
- 蘋果為何準備退出體育直播
- 埃克森美孚和西方石油導致內幕人士本月大量買入
- 家得寶業績指向低迷的下半年
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProQR治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧